Group 1 - The core point of the news is that Genting New Year (01952) has announced a subscription for 15.8462 million American Depositary Shares (ADS) of I-Mab at a price of $1.95 per ADS, totaling approximately $30.9 million [1][2] - Following the subscription, Genting New Year will hold a total of 15.8462 million ADS and 6.0786 million ordinary shares, representing about 16.1% of I-Mab's total issued share capital after the subscription [1] - I-Mab is a global biotechnology company focused on developing precision immuno-oncology drugs for cancer treatment, with three clinical-stage pipeline products [1] Group 2 - The board believes that the subscription confirms I-Mab's unique capabilities in clinical translation, particularly in the U.S., and complements Genting New Year's strong influence in Asia [2] - The collaboration is expected to create synergies between I-Mab's differentiated 4-1BB technology platform and bispecific antibody development pipeline, enhancing existing investments in mRNA cancer vaccines [2]

Group 1 - Company Gindalbie Metals Limited announced the subscription of 15.8462 million American Depositary Shares (ADS) of I-Mab at a price of $1.95 per ADS, totaling approximately $30.9 million [1] - After the subscription, the company will hold a total of 15.8462 million ADS and 6.0786 million ordinary shares, representing about 16.1% of I-Mab's total issued share capital post-transaction [1] - The company focuses on innovative drug and vaccine research and development, with a strategic pipeline of promising clinical-stage products and aims to address unmet medical needs globally [1] Group 2 - I-Mab is a global biotechnology company headquartered in the United States, specializing in precision immuno-oncology drugs for cancer treatment [2] - I-Mab has three clinical-stage pipeline products, including Givastomig, Ragistomig, and Uliledlimab, showcasing its unique capabilities in clinical translation [2] - The subscription is expected to create complementary and synergistic effects between I-Mab's strengths in the U.S. and the company's influence in the Asia-Pacific region, particularly in the area of mRNA cancer vaccines [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該 等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1952） Everest Medicines Limited 雲 頂 新 耀 有 限 公 司 自願性公告 本公告由雲頂新耀有限公司（「本公司」）自願作出。 本 公 司 董 事（「 董 事 」）會（「 董 事 會 」）宣 佈 ， 於 2025 年 8 月 1 日 ， 本 公 司 認 購 I -Mab （「 I -M a b 」）（ 一 間 於 納 斯 達 克 全 球 市 場 上 市 之 公 司 ， 股 份 代 號 為「 IM AB 」）之 15,846,154股美國預託股份（「ADS」）（ 每十(10)股ADS相當於二十三(23)股普通股 ） （「認購事項」），每股ADS為1.95美元（ 相當於約每股ADS 15.3港元 ）。認購事項之 總代價為30.9百萬美元（ 相當於約242.6百萬港元 ）。認購事項完成後，本公司將合 共持有15,846,154股ADS ...